SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : neog - Neogen's E.Coli Test adopted by Japan
NEOG 6.215+2.7%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kramer who wrote (201)6/5/1998 8:55:00 PM
From: Steve Lokness   of 441
 
Kevin, since you have criticized me for my "short sightedness", I would like to explain my reasons for being Surprised.

The company list several reasons for the shortfall, one of which as you have pointed out is certainly justified. However, they also mentioned weather conditions and a lack of sales of kits for vomitoxin. This may be true, but just last quarter they were bragging of increased sales and PROFIT despite a decrease in vomitoxin sales. The press release also list increased administration cost due to higher LEGAL fees. Where did these lawsuits come from?

Kevin, I did not buy my shares of NEOG as a short term investment, but I also believe I was not given a complete story by the company when I contacted them just prior to purchasing my shares. This is what surprises me.

I wish NEOG great success as I originally became interested in this company after my niece contacted E.coli. But I remain very surprised at the release today and find it a little disturbing.

Good Investing:
Steve
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext